Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Benznidazole (Primary) ; Fosravuconazole (Primary)
- Indications Chagas disease
- Focus Proof of concept; Therapeutic Use
- Acronyms BENDITA
- 01 Aug 2021 Status changed from active, no longer recruiting to completed, as per Results published in The Lancet Infectious Diseases
- 01 Aug 2021 Primary endpoint has been met. (Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.), as per Results published in The Lancet Infectious Diseases
- 01 Aug 2021 Results published in The Lancet Infectious Diseases